Proliferative Radiation Retinopathy after Plaque Radiotherapy for Uveal Melanoma

Carlos Bianciotto, Carol L. Shields, Cesare Pirondini, Arman Mashayekhi, Minoru Furuta, Jerry A. Shields

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: To determine risk factors, occurrence rate, management, and outcome of proliferative radiation retinopathy (PRR) after plaque radiotherapy for uveal melanoma. Design: Case-control study. Participants: Three thousand eight hundred forty-one patients who underwent plaque radiotherapy for uveal melanoma were entered into the study. Methods: Retrospective review of medical records. Main Outcome Measures: Proliferative radiation retinopathy after plaque radiotherapy for uveal melanoma. Results: Of 3841 eyes treated with plaque radiotherapy for uveal melanoma, PRR developed in 5.8% at 5 years and in 7% at 10 and 15 years using Kaplan-Meier analysis. The mean time to onset of PRR was 32 months (median, 30 months; range, 4-88 months). On univariate analysis, baseline factors predictive of PRR (P

Original languageEnglish
Pages (from-to)1005-1012
Number of pages8
JournalOphthalmology
Volume117
Issue number5
DOIs
Publication statusPublished - May 2010

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint Dive into the research topics of 'Proliferative Radiation Retinopathy after Plaque Radiotherapy for Uveal Melanoma'. Together they form a unique fingerprint.

Cite this